← All trials
NCT05797792
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2023
- Primary completion
- Mar 1, 2025
- Completion date
- May 1, 2025
- First posted
- Apr 4, 2023
- Last posted
- Apr 4, 2023
- Enrollment
- 440
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of BarcelonaLead sponsor
- University of BarcelonaOverall official - principal investigator
- University of BarcelonaCollaborator
- University of BarcelonaReponsible party - principal investigator
- Universidad Autonoma de BarcelonaOverall official - principal investigator
- Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaOverall official - principal investigator
- Hospital Universitario Central de AsturiasOverall official - principal investigator
- HOSPITAL UNIVERSITARIO DE CRUCESOverall official - principal investigator
- University of ValladolidOverall official - principal investigator
- Universidad de MurciaOverall official - principal investigator
- Universidad Carlos III MadridCollaborator
- University of BarcelonaOfficial
- Universidad Autonoma de BarcelonaOfficial
- University of ValladolidOfficial
- Hospital Universitario Central de AsturiasOfficial
- HOSPITAL UNIVERSITARIO DE CRUCESOfficial
- University of BarcelonaSponsor investigator
- Universidad de MurciaOfficial
- Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaOfficial
- Clinica Universidad de NavarraOfficial
- University of ValenciaOfficial
- OsakidetzaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.